SGLT2 Dapagliflozin May Lower Heart Failure Risk in Genetic Carriers
The new analysis of dapagliflozin, a diabetes drug, suggests it may cut heart failure risk dramatically for people who carry rare genetic variants tied to cardiomyopathy, based on data from a large randomized trial. Researchers examined over 12,000 adults with type 2 diabetes and elevated cardiovascular risk, focusing on roughly 121 carriers of potentially harmful...